- Conditions
- Alzheimer's Disease
- Interventions
- ONO-2506PO
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 9,512
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Hepatitis
- Interventions
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,085 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Gilbert, Arizona + 122 more
- Conditions
- Plaque Psoriasis
- Interventions
- Adalimumab, ABP 501
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 30 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 3,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- Malignant Neoplasm
- Interventions
- Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 319
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Belatacept, Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 17 more
- Conditions
- Solid Tumors
- Interventions
- Epacadostat, Nivolumab, Ipilimumab, Lirilumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
- Conditions
- Fabry Disease, Proteinuria
- Interventions
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
- Conditions
- Lichen Planopilaris
- Interventions
- Oral Brepocitinib, Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
- Interventions
- activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
- Conditions
- Long COVID, Long Covid19
- Interventions
- Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
- Drug
- Lead sponsor
- Kanecia Obie Zimmerman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 963 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Acne Vulgaris
- Interventions
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
- Conditions
- Abdominal Pain
- Interventions
- Endoscopic insufflation gas
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency
- Interventions
- somapacitan, somatropin, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 23 Years to 79 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more
- Conditions
- Amblyopia
- Interventions
- Vivid Vision, Luminopia, Optical Correction
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 46 more
- Conditions
- Leukemia
- Interventions
- cytarabine, idarubicin, lestaurtinib
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Draining Hematoma
- Interventions
- Standard Pressure Dressing, VAC
- Procedure · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
- Conditions
- Parkinson Disease
- Interventions
- DaTscan
- Drug
- Lead sponsor
- Ken Marek, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
- Conditions
- Osteoarthritis, Hypertension
- Interventions
- naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
- Drug
- Lead sponsor
- NicOx
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
- Conditions
- Idiopathic Focal Segmental Glomerulosclerosis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt ARD LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more